Supplementary Materials

Supplementary Material for:

An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model

Stefanie A. Krumm, Dan Yan, Elise S. Hovingh, Taylor J. Evers, Theresa Enkirch, G. Prabhakar Reddy, Aiming Sun, Manohar T. Saindane, Richard F. Arrendale, George Painter, Dennis C. Liotta, Michael G. Natchus, Veronika von Messling, Richard K. Plemper*

*Corresponding author. E-mail: rplemper@gsu.edu

Published 16 April 2014, Sci. Transl. Med. 6, 232ra52 (2014)
DOI: 10.1126/scitranslmed.3008517

This PDF file includes:

  • Fig. S1. Synthesis scheme of gram-scale production of ERDRP-0519.
  • Fig. S2. Shelf-stability assessment of ERDRP-0519.
  • Fig. S3. Adaptation profiles of CDV strains 5804PeH and Snyder Hill.
  • Fig. S4. ERDRP-0519 resistance sites in CDV L.
  • Fig. S5. Comparison of different vehicle dosing regimens in control animals.
  • Fig. S6. Clinical symptoms of treated and control animals infected with CDV- 5804PeH.
  • Fig. S7. Fever and body weight loss curves of infected animals.
  • Fig. S8. Challenge of animals of the PET group with a lethal CDV dose.
  • Fig. S9. In vitro resistance assessment of CDV reisolates from four different prophylactically dosed animals.
  • Fig. S10. Pathogenicity comparison of CDV-5804P-mKate and CDV-5804PeH.
  • Fig. S11. Contact transmission after single infection of source animals.
  • Table S1. Cytotoxicity of ERDRP-0519 in immortalized cell lines and primary human PBMCs.
  • Table S2. Oral PK profile of ERDRP-0519 in the ferret host.

[Download PDF]